Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study.

IF 1.3 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear Medicine and Molecular Imaging Pub Date : 2023-06-01 DOI:10.1007/s13139-023-00788-4

Marco Spadafora, Pasqualina Sannino, Luigi Mansi, Ciro Mainolfi, Rosario Capasso, Eugenio Di Giorgio, Salvatore Fiordoro, Serena Imbimbo, Filomena Masone, Laura Evangelista

{"title":"Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study.","authors":"Marco Spadafora, Pasqualina Sannino, Luigi Mansi, Ciro Mainolfi, Rosario Capasso, Eugenio Di Giorgio, Salvatore Fiordoro, Serena Imbimbo, Filomena Masone, Laura Evangelista","doi":"10.1007/s13139-023-00788-4","DOIUrl":null,"url":null,"abstract":"Purpose: This study is to use a simple algorithm based on patient's age to reduce the overall biological detriment associated with PET/CT.Materials and methods: A total of 421 consecutive patients (mean age 64 ± 14 years) undergoing PET for various clinical indications were enrolled. For each scan, effective dose (ED in mSv) and additional cancer risk (ACR) were computed both in a reference condition (REF) and after applying an original algorithm (ALGO). The ALGO modified the mean dose of FDG and the PET scan time parameters; indeed, a lower dose and a longer scan time were reported in the younger, while a higher dose and a shorter scan time in the older patients. Moreover, patients were classified by age bracket (18-29, 30-60, and 61-90 years).Results: The ED was 4.57 ± 0.92 mSv in the REF condition. The ACR were 0.020 ± 0.016 and 0.0187 ± 0.013, respectively, in REF and ALGO. The ACR for the REF and ALGO conditions were significantly reduced in males and females, although it was more evident in the latter gender (all p < 0.0001). Finally, the ACR significantly reduced from the REF condition to ALGO in all three age brackets (all p < 0.0001).Conclusion: Implementation of ALGO protocols in PET can reduce the overall ACR, mainly in young and female patients.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172419/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-023-00788-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study is to use a simple algorithm based on patient's age to reduce the overall biological detriment associated with PET/CT.

Materials and methods: A total of 421 consecutive patients (mean age 64 ± 14 years) undergoing PET for various clinical indications were enrolled. For each scan, effective dose (ED in mSv) and additional cancer risk (ACR) were computed both in a reference condition (REF) and after applying an original algorithm (ALGO). The ALGO modified the mean dose of FDG and the PET scan time parameters; indeed, a lower dose and a longer scan time were reported in the younger, while a higher dose and a shorter scan time in the older patients. Moreover, patients were classified by age bracket (18-29, 30-60, and 61-90 years).

Results: The ED was 4.57 ± 0.92 mSv in the REF condition. The ACR were 0.020 ± 0.016 and 0.0187 ± 0.013, respectively, in REF and ALGO. The ACR for the REF and ALGO conditions were significantly reduced in males and females, although it was more evident in the latter gender (all p < 0.0001). Finally, the ACR significantly reduced from the REF condition to ALGO in all three age brackets (all p < 0.0001).

Conclusion: Implementation of ALGO protocols in PET can reduce the overall ACR, mainly in young and female patients.

Abstract Image

查看原文本刊更多论文

减少PET/CT引起的整体生物损害的算法:一项基于年龄的研究。

目的:本研究旨在使用基于患者年龄的简单算法来减少PET/CT相关的整体生物学损害。材料与方法:共纳入421例连续接受PET治疗的患者(平均年龄64±14岁)。对于每次扫描，在参考条件下(REF)和应用原始算法(ALGO)后计算有效剂量(毫西弗单位的ED)和额外癌症风险(ACR)。算法修正了FDG的平均剂量和PET扫描时间参数;事实上，据报道，年轻患者的剂量较低，扫描时间较长，而老年患者的剂量较高，扫描时间较短。此外，患者按年龄分类(18-29岁、30-60岁和61-90岁)。结果:REF条件下的ED为4.57±0.92 mSv。REF和ALGO的ACR分别为0.020±0.016和0.0187±0.013。REF和ALGO的ACR在男性和女性中均显著降低，但后者更为明显(均p < 0.0001)。最后，在所有三个年龄组中，ACR从REF条件显著降低到ALGO条件(均p < 0.0001)。结论:在PET中实施ALGO方案可以降低总ACR，主要是在年轻和女性患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear Medicine and Molecular Imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

2.20

自引率

7.70%

发文量

期刊介绍： Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor. The Korean Society of Nuclear Medicine (KSNM) KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.